Clinical Focus Cardiff Oncology is a clinical-stage biotechnology company specializing in PLK1 inhibition with onvansertib, targeting difficult-to-treat cancers such as KRAS/NRAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma, indicating opportunities to partner on combination therapies with standard-of-care regimens.

Leadership & Strategy Recent leadership changes including the appointment of Mani Mohindru as CEO and interim-to-permanent leadership suggest a strategic reset and potential emphasis on advancing late-stage programs and commercial readiness, creating a window for strategic partnerships and co-development discussions.

Preclinical & IO Potential Active preclinical data presentations in collaboration with tumor-targeted strategies (for example with T-DXd) signal openness to collaboration on enabling science, translational research, and partner-driven expansion of the onvansertib portfolio across tumor vulnerabilities.

Investor & Market Signals Significant funding runway ($120M) with a lean commercial footprint and revenue under $1M indicates opportunity for investors and potential pharma partnerships to accelerate clinical programs, co-funding, or license deals to accelerate value realization.

Engagement & Visibility Active participation in major conferences (AACR, ASH) and ongoing investor communications demonstrate a focus on credibility-building and deal sourcing with potential licensees or collaborators seeking early access to data and collaboration opportunities.